Astellas Pharma Inc. is a Japanese multinational pharmaceutical company that operates in the Large Pharma sector. The company was founded in 2005 after the merger of Yamanouchi Pharmaceutical Co. Ltd. and Fujisawa Pharmaceutical Co. Ltd. Astellas Pharma is headquartered in Tokyo, Japan, and has operations in over 70 countries worldwide.

The company's mission is to contribute to the health of people around the world through the provision of innovative and reliable pharmaceutical products. Astellas Pharma is committed to sustainability and has set ambitious targets for decarbonisation and reducing its environmental impact.

Decarbonisation is a key priority for Astellas Pharma, and the company has set a target to reduce its greenhouse gas emissions by 30% by 2030, compared to its 2015 baseline. The company is committed to achieving this target through a range of measures, including energy efficiency improvements, the use of renewable energy, and the adoption of low-carbon technologies.

Corporate energy is another important focus area for Astellas Pharma. The company is committed to reducing its energy consumption and has set a target to achieve a 1% reduction in energy intensity each year. To achieve this target, Astellas Pharma is implementing a range of energy-saving measures, including the use of energy-efficient lighting, HVAC systems, and equipment.

Corporate power purchase agreements (PPAs) are also a key part of Astellas Pharma's sustainability strategy. The company has signed several corporate PPAs with renewable energy providers to source renewable energy for its operations. These agreements enable Astellas Pharma to reduce its carbon footprint and support the growth of renewable energy.

Renewable energy is a key focus area for Astellas Pharma, and the company is committed to sourcing 50% of its electricity from renewable sources by 2030. To achieve this target, the company is investing in renewable energy projects, such as solar and wind power, and is exploring new technologies, such as energy storage and electric vehicles.

In addition to its sustainability efforts, Astellas Pharma is committed to social responsibility and has a range of initiatives in place to support the communities in which it operates. The company's corporate social responsibility (CSR) activities include supporting healthcare initiatives, promoting diversity and inclusion, and contributing to disaster relief efforts.

Astellas Pharma's commitment to sustainability and social responsibility has been recognised by a range of external organisations. The company has been included in the Dow Jones Sustainability Indices (DJSI) for 13 consecutive years and has been named one of the world's most ethical companies by the Ethisphere Institute for five consecutive years.

In conclusion, Astellas Pharma Inc. is a Japanese multinational pharmaceutical company that operates in the Large Pharma sector. The company is committed to sustainability and has set ambitious targets for decarbonisation, reducing its environmental impact, and sourcing renewable energy. Astellas Pharma's commitment to social responsibility and its recognition by external organisations demonstrate its leadership in sustainability and its commitment to making a positive impact on the world.